Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species

被引:0
|
作者
Min, Byung-Joo [1 ]
Seo, Myung-Eui [2 ]
Bae, Jung Ho [3 ,4 ]
Kim, Ji Won [5 ,6 ]
Kim, Ju Han [7 ]
机构
[1] Seoul Inst, Natl Forens Serv, Forens DNA Div, Seoul, South Korea
[2] Seoul Natl Univ, Seoul Natl Univ Biomed Informat SNUBI, Coll Med, Dept Biomed Sci, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Healthcare Syst Gangnam Ctr, Dept Internal Med, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Healthcare Res Inst, Healthcare Syst Gangnam Ctr, Seoul, South Korea
[5] Seoul Natl Univ, Boramae Med Ctr, Dept Internal Med, Seoul Metropolitan Govt, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Seoul Natl Univ, Seoul Natl Univ Biomed Informat SNUBI, Coll Med, Div Biomed Informat, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
personalized Helicobacter pylori eradication treatment; individual antibiotic resistance profile; antibiotic resistance; proton-pump inhibitor metabolic phenotype; multispecies integrated next-generation sequencing panel; PENICILLIN-BINDING PROTEIN-1; 1ST-LINE TRIPLE THERAPY; AMOXICILLIN RESISTANCE; ANTIBIOTIC-RESISTANCE; MUTATIONS; RDXA; GENES; KOREA; FRXA; SUBSTITUTIONS;
D O I
10.3389/fcimb.2024.1379790
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: The decreasing Helicobacter pylori eradication rate is primarily attributed to antibiotic resistance, and further exacerbated by uniform drug administration disregarding a host's metabolic capability. Consequently, applying personalized treatment based on antibiotic resistance-associated variants and the host's metabolic phenotype can potentially increase the eradication rate. Method: A custom next-generation sequencing panel for personalized H. pylori eradication treatment (NGS-PHET) was designed which targeted the regions for amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin-resistance in H. pylori and human proton-pump inhibitor (PPI) metabolism. The libraries were constructed following customized methods and sequenced simultaneously. The customized framework criteria, grounded in previously reported antibiotic resistance associated variants and the host's PPI metabolism, was applied to the NGS-PHET results and suggested a personalized treatment for each subject, which was validated through each subject's actual eradication outcome. Results: Both previously reported and novel variants were identified from H. pylori sequencing results. Concurrently, five CYP2C19 homozygous extensive metabolizers and three CYP3A4 intermediate metabolizers were identified. Among the total of 12 subjects, clarithromycin triple therapy was suggested for five subjects, bismuth quadruple therapy was suggested for six subjects, and rifabutin triple therapy was suggested for one subject by following the customized framework criteria. The treatment suggestion for nine of the 12 subjects was consistent with the treatment that each subject achieved eradication with. Discussion: Applying the methodology using the NGS-PHET and customized framework helps to perform eradication treatment quickly and effectively in most patients with antibiotic-resistant H. pylori strains, and is also useful in research to find novel antibiotic-resistance candidates.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Next-generation sequencing: hype and hope for development of personalized radiation therapy?
    Tinhofer, Ingeborg
    Niehr, Franziska
    Konschak, Robert
    Liebs, Sandra
    Munz, Matthias
    Stenzinger, Albrecht
    Weichert, Wilko
    Keilholz, Ulrich
    Budach, Volker
    RADIATION ONCOLOGY, 2015, 10
  • [22] Next-generation sequencing: hype and hope for development of personalized radiation therapy?
    Ingeborg Tinhofer
    Franziska Niehr
    Robert Konschak
    Sandra Liebs
    Matthias Munz
    Albrecht Stenzinger
    Wilko Weichert
    Ulrich Keilholz
    Volker Budach
    Radiation Oncology, 10
  • [23] Development and Evaluation of a Next-Generation Sequencing Panel for the Multiple Detection and Identification of Pathogens in Fermented Foods
    Park, Dong-Geun
    Ha, Eun-Su
    Kang, Byungcheol
    Choi, Iseul
    Kwak, Jeong-Eun
    Choi, Jinho
    Park, Jeongwoong
    Lee, Woojung
    Kim, Seung Hwan
    Kim, Soon Han
    Lee, Ju-Hoon
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2023, 33 (01) : 83 - 95
  • [24] DEVELOPMENT AND VALIDATION OF NEXT-GENERATION SEQUENCING (NGS) BASED PGD
    Fedick, A.
    Tao, X.
    Devkota, B.
    Taylor, D.
    Scott, R. T., Jr.
    Treff, N. R.
    FERTILITY AND STERILITY, 2012, 98 (03) : S54 - S54
  • [25] The development of a next-generation sequencing panel targeting cannabinoid synthase genes to distinguish between marijuana and hemp
    Cheng, Ya-Chih
    Houston, Rachel
    ELECTROPHORESIS, 2024, 45 (9-10) : 948 - 957
  • [26] Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing
    Tran Thanh Binh
    Shiota, Seiji
    Suzuki, Rumiko
    Matsuda, Miyuki
    Tran Thi Huyen Trang
    Kwon, Dong Hyeon
    Iwatani, Shun
    Yamaoka, Yoshio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (07) : 1796 - 1803
  • [27] Validation and Utilization of a Clinical Next-Generation Sequencing Panel for Selected Cardiovascular Disorders
    Celestino-Soper, Patr-Cia B. S.
    Gao, Hongyu
    Lynnes, Ty C.
    Lin, Hai
    Liu, Yunlong
    Spoonamore, Katherine G.
    Chen, Peng-Sheng
    Vatta, Matteo
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2017, 4
  • [28] TECHNICAL VALIDATION OF A NEXT-GENERATION SEQUENCING PANEL FOR ACUTE MYELOID LEUKEMIA DIAGNOSIS
    Llop, M.
    Alonso, C. M.
    Ibanez, M.
    Cervera, J.
    Such, E.
    Pedrola, L.
    Martin, I.
    Onecha, E.
    Ayala, R.
    Sanz, M. A.
    Barragan, E.
    HAEMATOLOGICA, 2016, 101 : 665 - 665
  • [29] Validation of a next-generation sequencing oncology panel optimized for low input DNA
    Sussman, Robyn T.
    Shaffer, Sydney
    Azzato, Elizabeth M.
    DeSloover, Daniel
    Farooqi, Midhat S.
    Meyer, Anders
    Lieberman, David B.
    Bigdeli, Ashkan
    Paolillo, Carmela
    Ganapathy, Karthik
    Sukhadia, Shrey
    Rosenbaum, Jason N.
    Daber, Robert D.
    Morrissette, Jennifer J. D.
    CANCER GENETICS, 2018, 228 : 55 - 63
  • [30] Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
    Hannah L. Williams
    Kathy Walsh
    Austin Diamond
    Anca Oniscu
    Zandra C. Deans
    Virchows Archiv, 2018, 473 : 489 - 503